Skip to content

Efficacy of Polyethylene GlycolRecombinant Human Somatropin Injection in the treatment of idiopathic short stature children: a multicenter, observational study

Efficacy of Polyethylene GlycolRecombinant Human Somatropin Injection in the treatment of idiopathic short stature children: a multicenter, observational study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098245
Enrollment
Unknown
Registered
2025-03-05
Start date
2024-12-25
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic short stature

Interventions

Treatment group:None

Sponsors

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Provide an informed consent signed and dated by the study participant/legal guardian; 2. ISS children treated with PEGylated recombinant human growth hormone; 3. The height of the child was at or below the 3rd percentile or -2SDS of the height of a healthy child of the same age and sex before starting PEGylated recombinant human growth hormone therapy; 4. Age >= 4 years before starting PEGylated recombinant human growth hormone therapy; 5. Preadolescent (Tanner I stage and before) before starting PEGylated recombinant human growth hormone therapy; 6. No history of growth hormone therapy.

Exclusion criteria

Exclusion criteria: 1. Birth weight below P10 for children of the same age, sex and gestational age; 2. Known allergy to PEG rhGH or excipients; 3. Children with nutritional problems or chromosomal abnormalities; 4. Abnormal liver and kidney function (ALT > 1.5 times the upper limit of normal, Cr > the upper limit of normal); 5. Patients with endocrine systemic diseases, serious cardiopulmonary and blood system diseases, or systemic active infections, immunocompromised patients and psychiatric patients; 6. Patients who have had or currently have tumors, or who are undergoing screening for potential tumors (family history); 7. Other types of growth and development abnormalities, such as Turner syndrome, Laron syndrome, growth hormone receptor deficiency, etc.; 8. Have participated in other drug clinical trials within 3 months; 9. Other conditions deemed unsuitable for inclusion in this clinical study by the investigator.

Design outcomes

Primary

MeasureTime frame
?HtSDS after 52 weeks of use;

Secondary

MeasureTime frame
?HV(52weeks);PedsQL;?IGF-1 ??IGF-/IGFBP-3(52weeks);?IGF-1 ??IGF-/IGFBP-3(104weeks);

Countries

China

Contacts

Public ContactLing Hou

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology

linghou@tjh.tjmu.edu.cn+86 27 63639960

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026